GS:NYSEGoldman Sachs Group, Inc. (The) Analysis
Data as of 2026-03-09 - not real-time
$831.91
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Goldman Sachs is trading at $831.91, comfortably above its 200‑day SMA of $789.7 but below the 20‑day ($896) and 50‑day ($917) averages, indicating a short‑term pull‑back within a longer‑term uptrend. The RSI of 35.8 suggests the stock is approaching oversold territory, while a bearish MACD histogram reinforces downside pressure. Volatility remains elevated at 37% over the past 30 days and a beta of 1.33 points to heightened market sensitivity. On the valuation side, the trailing P/E of 16.2 is modestly below the industry average of 17.4 and the forward P/E of 12.8 signals attractive earnings growth ahead. A dividend yield of 2.19% with a 27% payout ratio appears sustainable given the company’s $996 B cash balance that exceeds its $748 B debt. Revenue grew 15% YoY and ROE sits near 14%, but operating cash flow is negative, highlighting cash‑flow pressure. Analyst sentiment is cautiously optimistic, with UBS lifting the mean price target to $959 and a median of $982, implying roughly 15% upside. However, recent congressional scrutiny over past conduct and heightened attention on its private‑lending expansion raise regulatory concerns. The firm’s strategic investment in AI‑governance partner Schellman may diversify fee revenue streams. Overall, the stock sits at a valuation discount to analyst expectations, supported by a solid dividend but tempered by short‑term technical weakness and regulatory headwinds.
Given the mixed technical signals, strong fundamentals, and a favorable earnings outlook, investors should consider a measured approach: maintain exposure while monitoring support levels and regulatory developments.
Given the mixed technical signals, strong fundamentals, and a favorable earnings outlook, investors should consider a measured approach: maintain exposure while monitoring support levels and regulatory developments.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and RSI near oversold levels
- Proximity to support at $795
- Elevated regulatory scrutiny
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervaluation relative to analyst price targets
- Strong earnings growth and forward P/E advantage
- Sustainable dividend yield
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Robust cash position and dividend consistency
- Diversified revenue streams including AI‑governance partnership
- Resilient brand and market position despite regulatory risk
Key Metrics & Analysis
Financial Health
Revenue Growth15.20%
Profit Margin28.92%
P/E Ratio16.2
ROE13.86%
ROA0.99%
Debt/Equity596.07
P/B Ratio2.3
Op. Cash Flow$-45154000896
Industry P/E17.4
Technical Analysis
TrendNeutral
RSI35.8
Support$795.00
Resistance$968.39
MA 20$896.03
MA 50$916.94
MA 200$789.72
MACDBearish
VolumeIncreasing
Fear & Greed Index100
Valuation
Target Price$959.20
Upside/Downside15.30%
GradeUndervalued
TypeBlend
Dividend Yield2.19%
Risk Assessment
Beta1.33
Volatility37.37%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.